Business Wire

AL-ADTRAN

23.5.2024 14:01:26 CEST | Business Wire | Press release

Share
Adtran celebrates 75 years of Oscilloquartz network timing innovation

Adtran today announced that this month marks the 75th anniversary of Oscilloquartz. Founded in 1949, Oscilloquartz has evolved into a global leader in PNT network timing technology, setting numerous industry benchmarks throughout its history. The company offers precision synchronization solutions that empower customers to overcome timing challenges in sectors from telecoms to critical defense infrastructure. Over the years, Oscilloquartz has consistently led the way with groundbreaking achievements, such as introducing the industry’s first optical cesium atomic clocks with optical pumping technology, which provide unparalleled accuracy and reliability. This month also commemorates 10 years since Oscilloquartz was acquired by ADVA, now part of Adtran, helping it expand its portfolio of cost-effective timing technologies and establish the leading assured PNT platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240523252321/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Adtran’s Oscilloquartz timing technology is playing a key role in helping organizations strengthen critical network infrastructure. (Photo: Business Wire)

“Celebrating 75 years of Oscilloquartz, alongside a decade since our integration into the Adtran family, represents a remarkable achievement. The dual anniversary highlights our enduring commitment to timing innovation and quality. Throughout these decades, we’ve navigated the evolving landscape from frequency solutions for legacy SONET/SDH to highly accurate frequency and time solutions for packet-based networks. Our dedication has enabled us to offer scalable technology that ensures robust timing, with or without satellite signals,” said Gil Biran, GM of Oscilloquartz, Adtran. “From pioneering the integration of synchronization delivery and assurance to bringing timing closer to end applications through our compact, low-power devices, including our latest family of OSAinside products, our portfolio has consistently addressed our customers’ key challenges. More recently, the introduction of the first commercial optical cesium atomic clocks was another major leap, significantly enhancing the precision and stability of network timing while substantially extending lifespan.”

Since its inception, Oscilloquartz has led the field in network synchronization, setting standards with the industry’s first commercial magnetic cesium atomic clock in 1966 and spearheading telecoms timing solutions in 1978. In 1982, it transformed the market by introducing the first high-performance quartz oscillators and resonators, which played a key role in developing the European Digital Cesium Standard in 1988. After its acquisition in 2014, Oscilloquartz expanded its global presence, with leading service providers adopting its products. It also provided customized solutions across metrology, finance and national defense sectors. Its leadership in cesium clock technology won support for its R&D initiatives from the European Space Agency. Continuing its legacy of innovation, Oscilloquartz recently enhanced the resiliency of GPS/GNSS systems with its Iridium®-based Satellite Time and Location (STL) technology solutions, leveraging low-Earth orbit satellite signals for more reliable, secure synchronization even in challenging environments.

“This historic anniversary is a moment to appreciate Oscilloquartz’s incredible journey, from its initial project at the astronomical observatory in Neuchâtel 70 years ago to the forefront of timing technology today,” commented Christoph Glingener, CTO of Adtran. “Over the last decade, the integration with ADVA and then Adtran has enriched Oscilloquartz’s offerings through the combined expertise of our teams. This era saw the debut of compact and cost-effective Oscilloquartz synchronization devices, delivering unmatched precision at the network edge. Its core grandmasters set new industry benchmarks with their 10GbE support and hardware timestamping. Together with Oscilloquartz’s optical atomic cesium clocks, they create a SePRTC+, guaranteeing accurate, reliable timing even during GNSS disruptions for up to 100 days. This combination of the industry’s most scalable family of grandmasters based on zero-trust architecture, coupled with optical pumping technology, sets Oscilloquartz apart today. As part of the Adtran family, Oscilloquartz will continue its legacy of excellence, keeping customers at the forefront of synchronization technology.”

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

Published by
ADTRAN Holdings, Inc.
www.adtran.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240523252321/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye